CD38 (ADP Ribosyl Cyclase 1) Antibody - Without BSA and Azide
Mouse Monoclonal Antibody [Clone FS02 ]
|Application ||IF, FC|
|Other Accession||952, 479214|
|Isotype||Mouse / IgG1, kappa|
|Calculated MW||~45kDa (Glycoprotein); 35kDa (protein core)|
|Other Names||ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, 22.214.171.124, 2'-phospho-ADP-ribosyl cyclase, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, 126.96.36.199, 2'-phospho-cyclic-ADP-ribose transferase, ADP-ribosyl cyclase 1, ADPRC 1, Cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10, CD38, CD38|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD38 (ADP Ribosyl Cyclase 1) Antibody - Without BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger for glucose-induced insulin secretion. Also has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system.|
|Cellular Location||Membrane; Single-pass type II membrane protein|
|Tissue Location||Expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This antibody reacts with a type II membrane glycopeptide with a transmembrane sequence near the NH2-terminus. CD38 is a type II transmembrane glycoprotein that is present on early B- and T-cell lineages and activated B- and T-cells but is absent from most mature resting peripheral lymphocytes. CD38 is also found on thymocytes, pre-B cells, germinal center B-cells, mitogen-activated T-cells, monocytes and Ig-secreting plasma cells. CD38 is expressed on CD34+ cells. The CD34+CD38- population of hematopoietic stems cells defines the most pluripotent cells (e.g. blast colony forming cells).
Deaglio S et. al. J Immunol. 1998;160(1):395-402
If you have any additional inquiries please email technical services at firstname.lastname@example.org.